The FDA disappointed AstraZeneca and its investors by not approving its heart drug Brilinta, a blood-thinner that the company — facing a severe patent cliff — has high hopes for. If approved, it could be a multibillion-dollar…
As part of its efforts to expand into the biotech market, Johnson & Johnson is making a long-anticipated bid for Dutch vaccine maker Crucell — in spite of Crucell’s recent manufacturing troubles.
Continue read…
Eli Lilly’s blockbuster antidepressant Cymbalta can now also be marketed as a treatment for chronic musculoskeletal pain, such as osteoarthritis and lower back pain, following FDA approval yesterday.
Continue r…
The world’s biggest drugmaker reported earnings of $4.4 billion that topped estimates but revenues of $16.2 billion fell short of expectations.
Continue reading Pfizer Earnings Top Estimates, Boosts Guidance
…
At a recent life-sciences conference in Stockholm, execs of several U.S. and foreign biotechs clashed with Big Pharma in a lively debate on the merits of their respective goals and products. The result, however, was a stand-off…